Literature DB >> 15357661

Oxidation of melatonin and its catabolites, N1-acetyl-N2 -formyl-5-methoxykynuramine and N1-acetyl-5-methoxykynuramine, by activated leukocytes.

Sueli O Silva1, Maria R Rodrigues, Sandra R Q Carvalho, Luiz H Catalani, Ana Campa, Valdecir F Ximenes.   

Abstract

N(1)-acetyl-N(2)-formyl-5-methoxykynuramine (AFMK) and N(1)-acetyl-5-methoxykynuramine (AMK), two melatonin catabolites, have been described as potent antioxidants. We aimed to follow the kinetics of AFMK and AMK formation when melatonin is oxidized by phorbol myristate acetate (PMA) and lipopolysaccharide (LPS)-activated leukocytes. An HPLC-based method was used for AFMK and AMK determination in neutrophil and peripheral blood mononuclear cell cultures supernatants. Samples were separated isocratically on a C18 reverse-phase column using acetonitrile/H(2)O (25:75) as the mobile phase. AFMK was detected by fluorescence (excitation 340 nm and emission 460 nm) and AMK by UV-VIS absorbance (254 nm). Activation of neutrophils and mononuclear cells with PMA produces larger amounts of AFMK than activation with LPS, probably due to the lower levels of reactive oxygen species formation and myeloperoxidase (MPO) degranulation that occurs when cells are stimulated with LPS. The concentration of AMK found in the supernatant was about 5-10% (from 18-hr cultures) compared with AFMK. This result may reflect its reactivity. Indeed AMK, but not AFMK, is easily oxidized by activated neutrophils in a MPO and hydrogen peroxide-dependent reaction. In conclusion, we defined a simple procedure for the determination of AFMK and AMK in biological samples and demonstrated the capacity of leukocytes to oxidize melatonin and AMK.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15357661     DOI: 10.1111/j.1600-079X.2004.00149.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  19 in total

1.  Urinary metabolites and antioxidant products of exogenous melatonin in the mouse.

Authors:  Xiaochao Ma; Jeffrey R Idle; Kristopher W Krausz; Dun-Xian Tan; Leopoldo Ceraulo; Frank J Gonzalez
Journal:  J Pineal Res       Date:  2006-05       Impact factor: 13.007

Review 2.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

Review 3.  A review of the multiple actions of melatonin on the immune system.

Authors:  Antonio Carrillo-Vico; Juan M Guerrero; Patricia J Lardone; Russel J Reiter
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

4.  Influence of melatonin and acetylsalicylic acid on lipid peroxidation and antioxidant enzyme activities in gastric mucosa.

Authors:  Tetsuya Mine
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

5.  Effects of melatonin or acetylsalicylic acid on gastric oxidative stress after bile duct ligation in rats.

Authors:  Alaaddin Polat; Memet Hanifi Emre
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

6.  Evaluation of melatonin and AFMK levels in women with breast cancer.

Authors:  Tialfi Bergamin de Castro; Newton Antônio Bordin-Junior; Eduardo Alves de Almeida; Debora Aparecida Pires de Campos Zuccari
Journal:  Endocrine       Date:  2018-05-24       Impact factor: 3.633

Review 7.  Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance.

Authors:  Rüdiger Hardeland
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 8.  Measurement of melatonin and its metabolites: importance for the evaluation of their biological roles.

Authors:  Glaucia R Martinez; Eduardo A Almeida; Clécio F Klitzke; Janice Onuki; Fernanda M Prado; Marisa H G Medeiros; Paolo Di Mascio
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 9.  Role of melatonin in neurodegenerative diseases.

Authors:  V Srinivasan; S R Pandi-Perumal; G Jm Maestroni; A I Esquifino; R Hardeland; D P Cardinali
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

10.  Melatonin ameliorates cerebral vasospasm after experimental subarachnoidal haemorrhage correcting imbalance of nitric oxide levels in rats.

Authors:  M A Aladag; Y Turkoz; H Parlakpinar; H Ozen; M Egri; S C Unal
Journal:  Neurochem Res       Date:  2009-05-05       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.